EGFR and gastric cancer: To further investigate whether acquisition of a pro-metastatic phenotype, was mediated by EGF-R phosphorylation gastric cancer cells exposed to TLCA, were treated with cetuximab, an EGF-R inhibitor, or with U0126, an inhibitor of the ERK1 and ERK2.